Previous 10 | Next 10 |
Highlights Fourth quarter revenue of $1,373.4 million increased 20.5% year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $357.1 million for the fourth quarter, a year-over-year decline of 72.9%...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $1.43 (+28.8% Y/Y) and the consensus Revenue Estimate is $1.4B (+22.8% Y/Y). Over the last 2 years, SYNH has beaten EPS estimates 100% of the ...
Bruker Corporation has been performing exceptionally well as of late, driven by strong sales growth and an increase in profits. However, it's uncertain whether recent moves higher on its top and bottom lines are here to stay. At best, shares look to be fairly valued, with the poss...
MORRISVILLE, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its fourth quarter and full year 2021 financial results on Thursday, Feb...
MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors...
MORRISVILLE, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 12 th annual Dealmakers’ Intentions Survey. Conducted on an annual basis, the survey provides a revi...
MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, today announced that Chief Executive Officer Alistair Macdonald is scheduled to prese...
MORRISVILLE, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released 2022 Health Trends: Insights for Industry Change Agents . From patient-powered design to accelerated integratio...
Syneos Health is delivering on its promises as the company reports strong revenue and free cash flow growth. The free cash flow is roughly twice as high compared to the net income due to lower capex requirements and high share-based compensation elements. The free cash flow is spe...
Syneos Health Inc. (NASDAQ:SYNH) said it's not engaged in discussions on a potential combination or transaction with LabCorp. (NYSE:LH) or any of its businesses or divisions, according to an 8-K filing. Syneos rose 4.5% in premarket trading, LabCorp. fell 1.1%. The disclosure comes ...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...